{"id":"etc-1002","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Gout"},{"rate":null,"effect":"Elevated uric acid levels"},{"rate":null,"effect":"Tendon rupture"}]},"_chembl":{"chemblId":"CHEMBL3545313","moleculeType":"Small molecule","molecularWeight":"344.49"},"_fixedAt":"2026-03-30T16:01:49.152330","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ETC-1002 is an AMPK activator that works through dual mechanisms: it inhibits acetyl-CoA carboxylase (ACC), reducing fatty acid and cholesterol synthesis in the liver, and simultaneously increases cholesterol catabolism and excretion. This dual action results in significant reductions in LDL cholesterol and triglycerides, making it a novel approach to dyslipidemia management.","oneSentence":"ETC-1002 activates AMP-activated protein kinase (AMPK) to reduce cholesterol synthesis and increase cholesterol catabolism, thereby lowering LDL cholesterol levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:11:42.823Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia (as monotherapy or in combination with statins)"},{"name":"Cardiovascular risk reduction in patients with elevated LDL cholesterol"}]},"_fixedFields":["sideEffects","pubmed(44)","modality→Small Molecule"],"trialDetails":[{"nctId":"NCT05687071","phase":"PHASE3","title":"A Long-term Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2023-02-27","conditions":"Hyper-low-density Lipoprotein (LDL) Cholesterolemia","enrollment":130},{"nctId":"NCT05694260","phase":"PHASE2","title":"A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2023-01-12","conditions":"Hypercholesterolemia","enrollment":31},{"nctId":"NCT05683340","phase":"PHASE3","title":"A Confirmatory Trial of ETC-1002 in Patients With Hyper-LDL Cholesterolemia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2023-02-13","conditions":"Hyper-low-density Lipoprotein (LDL) Cholesterolemia","enrollment":96},{"nctId":"NCT04784442","phase":"PHASE2","title":"A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2021-03-24","conditions":"Hypercholesterolemia","enrollment":188},{"nctId":"NCT02993406","phase":"PHASE3","title":"Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2016-12-22","conditions":"Cardiovascular Diseases, Statin Adverse Reaction","enrollment":13970},{"nctId":"NCT02178098","phase":"PHASE2","title":"Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2014-06-16","conditions":"Hypercholesterolemia, Hypertension","enrollment":143},{"nctId":"NCT01751984","phase":"PHASE2","title":"A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2012-10-04","conditions":"Hypercholesterolemia","enrollment":56},{"nctId":"NCT01262638","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2010-12","conditions":"Dyslipidemia","enrollment":177},{"nctId":"NCT03067441","phase":"PHASE3","title":"Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2017-02-03","conditions":"Hypercholesterolemia, Atherosclerotic Cardiovascular Disease","enrollment":1462},{"nctId":"NCT02666664","phase":"PHASE3","title":"Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2016-01-21","conditions":"Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases","enrollment":2230},{"nctId":"NCT03001076","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2016-11-29","conditions":"Hypercholesterolemia, Atherosclerosis, Statin Adverse Reaction","enrollment":269},{"nctId":"NCT02991118","phase":"PHASE3","title":"Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2016-11-18","conditions":"Hypercholesterolemia, Atherosclerotic Cardiovascular Disease","enrollment":779},{"nctId":"NCT03337308","phase":"PHASE3","title":"A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2017-10-23","conditions":"Hyperlipidemias","enrollment":382},{"nctId":"NCT03051100","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2017-01-19","conditions":"Hypercholesterolemia","enrollment":63},{"nctId":"NCT03193047","phase":"PHASE2","title":"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2017-04-07","conditions":"Hypercholesterolemia","enrollment":59},{"nctId":"NCT02988115","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2016-11-16","conditions":"Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Statin Adverse Reaction","enrollment":345},{"nctId":"NCT02659397","phase":"PHASE2","title":"A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2015-12","conditions":"Hyperlipidemia","enrollment":68},{"nctId":"NCT01779453","phase":"PHASE2","title":"A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2012-12","conditions":"Hypercholesterolemia","enrollment":58},{"nctId":"NCT02072161","phase":"PHASE2","title":"Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2014-03","conditions":"Hypercholesterolemia","enrollment":133},{"nctId":"NCT01941836","phase":"PHASE2","title":"Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2013-09","conditions":"Hypercholesterolemia","enrollment":349},{"nctId":"NCT01607294","phase":"PHASE2","title":"A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2012-04","conditions":"Hyperlipidemia, Type 2 Diabetes","enrollment":60},{"nctId":"NCT01485146","phase":"PHASE1","title":"A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2011-10-25","conditions":"Safety Evaluation of Escalating Doses","enrollment":24},{"nctId":"NCT01105598","phase":"PHASE1","title":"A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2010-04-20","conditions":"Mild Dyslipidemia","enrollment":53},{"nctId":"NCT02044627","phase":"PHASE1","title":"Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002","status":"COMPLETED","sponsor":"Esperion Therapeutics, Inc.","startDate":"2013-12","conditions":"Hyperlipidemia","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"recentPublications":[{"date":"2025 Nov","pmid":"41014810","title":"Association of Uric Acid-Lowering Therapies on Gout Frequency with Bempedoic Acid: Clinical Insights From CLEAR Outcomes.","journal":"JACC. Advances"},{"date":"2006","pmid":"33104321","title":"Bempedoic Acid.","journal":""},{"date":"2025 Feb","pmid":"39694195","title":"The combination of gemcitabine and albumin-bound paclitaxel effectively inhibits de novo lipogenesis in pancreatic cancer cells by targeting the AMPK/SREBP1 pathway.","journal":"Biochemical pharmacology"},{"date":"2024 Jul 9","pmid":"38960508","title":"Comparative Cardiovascular Benefits of Bempedoic Acid and Statin Drugs.","journal":"Journal of the American College of Cardiology"},{"date":"2023 May","pmid":"36878717","title":"The Disposition and Metabolism of Bempedoic Acid, a Potent Inhibitor of ATP Citrate Lyase, in Healthy Human Subjects.","journal":"Drug metabolism and disposition: the biological fate of chemicals"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["bempedoic acid"],"phase":"phase_3","status":"active","brandName":"ETC-1002","genericName":"ETC-1002","companyName":"Esperion Therapeutics, Inc.","companyId":"esperion-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ETC-1002 activates AMP-activated protein kinase (AMPK) to reduce cholesterol synthesis and increase cholesterol catabolism, thereby lowering LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia (as monotherapy or in combination with statins), Cardiovascular risk reduction in patients with elevated LDL cholesterol.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":4,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}